This is description for ETL program in basic details tab
Share
Released: July 06, 2023
Expires: July 06, 2024
Released: April 23, 2024
Expires: April 23, 2025
Released: May 31, 2024
Expires: May 31, 2025
Released: June 05, 2024
Expires: June 05, 2025
Released: July 10, 2024
Expires: July 10, 2025
Released: August 07, 2024
Expires: August 07, 2025
Released: August 29, 2024
Expires: August 29, 2025
Released: July 01, 2018
Expires: August 23, 2018
Released: October 02, 2024
Expires: October 02, 2025
Released: January 24, 2025
Expires: January 24, 2026
Emmanuel S. Antonarakis, MBBCh
Professor
Department of Oncology and Urology
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Scott Antonia, MD, PhD
Chair
Medical Oncologist
Department of Thoracic Oncology
Moffitt Cancer Center
Tampa, Florida
Frederick R. Appelbaum, MD
Professor and Head
Department of Medical Oncology
University of Washington Medical Center
Member and Director
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington
Cathy Eng, MD
Professor of Medicine, Hematology, and Oncology
Co-Leader
Gastrointestinal Cancer Research Program
Co-Director
Gastrointestinal Oncology
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, Tennessee
Prof. Dr. med. Sibylle Loibl
Professor
Goethe University
Clinical Consultant
Centre for Haematology and Oncology
Frankfurt am Main, Germany
Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI
Full Professor of Microbial Diseases
Director, Centre for Experimental Pathogen Host Research
School of Medicine
University College Dublin
Dublin, Ireland
Lauren M. Osborne, MD
(Program Chair)
Vice Chair for Clinical Research, Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York
Jae H. Park, MD
Chief, Cellular Therapy Service
Attending Physician, Leukemia Service
Professor of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Abbott Diabetes Care Inc.
IOIBD
This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.
A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities?
Activity Description
This educational activity will address the issue of adherence in the oncology patient. Adherence is one of the most important factors to address to increase the likelihood of treatment success. More oral chemotherapy agents are becoming available for oncology treatments, increasing the importance of adherence. Topics to be addressed include the incidence of non-adherence, reasons for non-adherence, and consequences of non-adherence. Strategies to remove barriers to non-adherence and improve the adherence rate will be discussed.
Target Audience
The target audience for this activity includes pharmacists, pharmacy technicians and nurses.
Learning Objectives
Upon completion of this activity, participants will be able to:
Discuss the shift from intravenous to oral chemotherapy over the past few decades
Assess the various dimensions of adherence
Discuss how to manage patients who are non-adherent to oral chemotherapy
Explain how to advocate for legislation that can improve access to oral chemotherapy
Faculty
Benyam Muluneh, PharmD, BCOP, CPP
Clinical Pharmacist Practitioner
Adjunct Assistant Professor
Malignant Hematology Clinic
UNC Hospitals
Chapel Hill, NC
CME/CE Accreditation
ACPE Release Date: 02-27-2020
Nurse Release Date: 09-01-2021
Expiration Date: 02-27-2023
ACPE Credit Designation (Pharmacist and Pharmacy Technician CE)This CE activity is jointly provided by ProCE, LLC and the National Association of Specialty Pharmacy (NASP). ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-089-H01-P/T has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
Joint Accreditation StatementIn support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing EducationThe maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Disclosure
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty and planners reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Benyam Muluneh has no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Jason J. Everly, PharmD, BCOP, CHCP has no relevant conflicts of interest to report.
Robin Wanous-Williamson (nurse planner) has no relevant conflicts of interest to report.
Potential conflicts of interest were resolved with a peer review process provided by Jason J. Everly, PharmD, BCOP, CHCP.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Funding
This activity is self-funded by NASP.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
Primary Author
Emmanuel S. Antonarakis, MBBCh
Professor
Department of Oncology and Urology
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Prof. Dr. med. Sibylle Loibl,
Professor
Goethe University
Clinical Consultant
Centre for Haematology and Oncology
Frankfurt am Main, Germany
Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI
Full Professor of Microbial Diseases
Director, Centre for Experimental Pathogen Host Research
School of Medicine
University College Dublin
Dublin, Ireland
Patrick W. Mallon, MB, BCh, PhD, FRACP, FRCPI: consultant/advisor/speaker: Gilead Sciences, ViiV Healthcare. Test test test
Jae H. Park, MD
Chief, Cellular Therapy Service
Attending Physician, Leukemia Service
Professor of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Jae H. Park, MD: consultant/advisor/speaker: Adaptive Technologies, AffyImmune, Allogene, Amgen, Artiva Biotherapeutics, Autolus, Be Biopharma, BeiGene, Bright Pharmaceuticals, Bristol Myers Squibb, Caribou Biosciences, Curocell, Galapagos, IN8Bio, Kite, Kura Oncology, Minerva, Novartis, Pfizer, Servier, Synthekine, Takeda.
Scott Antonia, MD, PhD
Chair
Medical Oncologist
Department of Thoracic Oncology
Moffitt Cancer Center
Tampa, Florida
Testing scott
Frederick R. Appelbaum, MD
Professor and Head
Department of Medical Oncology
University of Washington Medical Center
Member and Director
Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington
testing frederick
Lauren M. Osborne, MD
(Program Chair)
Vice Chair for Clinical Research, Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York
tesing lauren